



上海源叶生物科技有限公司  
Shanghai Yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: www.shyuanye.com  
邮箱: shyysw@sina.com

产品名称: TP-3654

产品别名: TP-3654

**生物活性:**

<b>Description</b>	TP-3654 is a second-generation Pim kinase inhibitor with $K_i$ values of 5 and 42 nM for Pim-1 and Pim-3, respectively.																												
<b>IC<sub>50</sub> &amp; Target</b>	Ki: 5 nm(Pim-1), 239 nM (Pim-2), 42 nM (Pim-3) <sup>[1]</sup>																												
<b>In Vitro</b>	TP-3654 demonstrates potent PIM-1 specific cellular activity in the PIM-1/BAD overexpression system with an average EC <sub>50</sub> of 67 nM. TP-3654 treatment reduces levels of phospho-BAD <i>in vitro</i> using the bladder cancer cell line UM-UC-3. TP-3654 reduces colony growth of T24 and UM-UC3 cells, confirming the PIM-1-dependent growth for both cell lines <sup>[1]</sup> .																												
<b>In Vivo</b>	Oral dosing of 200 mg/kg TP-3654 significantly reduces both UM-UC-3 and PC-3 tumor growth measured by volume (caliper) and by final tumor weight, with no significant changes in body weight or gross adverse toxicity <sup>[1]</sup> .																												
<b>Solvent&amp;Solubility</b>	<p><b>In Vitro:</b></p> <p>DMSO : 50 mg/mL (119.49 mM; Need ultrasonic)</p> <p>H<sub>2</sub>O : &lt; 0.1 mg/mL (insoluble)</p> <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent</th><th>Mass</th><th>Concentration</th><th></th></tr><tr><th></th><th>1 mg</th><th></th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td>1 mM</td><td>2.3897 mL</td><td></td><td>11.9486 mL</td><td>23.8971 mL</td></tr><tr><td>5 mM</td><td>0.4779 mL</td><td></td><td>2.3897 mL</td><td>4.7794 mL</td></tr><tr><td>10 mM</td><td>0.2390 mL</td><td></td><td>1.1949 mL</td><td>2.3897 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution</p> <p>此方案可获得 ≥ 2.08 mg/mL (4.97 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例, 取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀, 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline)</p> <p>Solubility: 2.08 mg/mL (4.97 mM); Precipitated solution; Need ultrasonic</p> <p>此方案可获得 2.08 mg/mL (4.97 mM)</p>				Preparing Stock Solutions	Solvent	Mass	Concentration			1 mg		5 mg	10 mg	1 mM	2.3897 mL		11.9486 mL	23.8971 mL	5 mM	0.4779 mL		2.3897 mL	4.7794 mL	10 mM	0.2390 mL		1.1949 mL	2.3897 mL
Preparing Stock Solutions	Solvent	Mass	Concentration																										
		1 mg		5 mg	10 mg																								
1 mM	2.3897 mL		11.9486 mL	23.8971 mL																									
5 mM	0.4779 mL		2.3897 mL	4.7794 mL																									
10 mM	0.2390 mL		1.1949 mL	2.3897 mL																									



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 20.8 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 20% 的 SBE-<math>\beta</math>-CD 生理盐水水溶液中, 混合均匀。</p> <p>3.请依序添加每种溶剂: 10% DMSO → 90% corn oil</p> <p>Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution</p> <p>此方案可获得 ≥ 2.08 mg/mL (4.97 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 20.8 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中, 混合均匀。</p>
<b>References</b>	[1]. Foulks JM, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. <i>Neoplasia</i> . 2014 May;16(5):403-12.
<b>实验参考:</b>	
<b>Cell Assay</b>	1 $\mu$ M TP-3654 is tested against 336 kinases at a concentration of 10 $\mu$ M ATP. IC <sub>50</sub> determinations of phosphoinositide 3-kinase (PI3K) ( $\alpha$ , $\beta$ , $\delta$ , and $\gamma$ ) and all kinases inhibited by >50% from the initial screen are performed using 10-dose, three-fold serial dilutions of TP-3654 starting with 10 $\mu$ M at K <sub>m</sub> ATP concentrations for each kinase <sup>[1]</sup> .
<b>Animal Administration</b>	When tumors of mice reaches 100 to 200 mm <sup>3</sup> by caliper measurement, mice are randomized, and oral dosing of TP-3654 or vehicle control began and continued every day for 5 days with 2 days off for 18 to 21 days. Tumor volumes and body weights were determined twice a week <sup>[1]</sup> .
<b>References</b>	[1]. Foulks JM, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. <i>Neoplasia</i> . 2014 May;16(5):403-12.

# 源叶生物